Physician profile
Stephen J Saxe
NPI 1699750844
$609.70
in general payments reported to CMS, 2019-2025
12 companies · $32.89 in 2025
The $32.89 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.43 · 2020: $75.46 · 2021: $104 · 2022: $113 · 2023: $117 · 2024: $125 · 2025: $32.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $219.46 | 2019-2022 | |
| Genentech USA, INC. | $93.19 | 2022-2024 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $60.83 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $52.66 | 2023-2025 | Syfovre |
| Abbvie INC. | $38.22 | 2023-2025 | Ozurdex |
| Alimera Sciences, INC. | $27.58 | 2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $25.35 | 2024 | Izervay |
| Eyepoint US, INC. | $21.27 | 2023 | |
| Bausch & Lomb Americas INC. | $20.33 | 2022 | |
| Amgen INC. | $17.64 | 2024 | |
| Allergan, INC. | $17.20 | 2020 | |
| Harrow Eye, LLC | $15.97 | 2023 | Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Saxe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.